Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

I read the 8K SEC filing and the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Lorcan458 Member Profile
 
Followed By 0
Posts 55
Boards Moderated 0
Alias Born 09/14/16
160x600 placeholder
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Rese... PR Newswire (US) - 5/27/2020 7:25:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/8/2020 12:05:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 6:32:09 AM
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update GlobeNewswire Inc. - 5/7/2020 6:30:10 AM
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European U... GlobeNewswire Inc. - 5/7/2020 1:00:10 AM
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology GlobeNewswire Inc. - 5/4/2020 3:30:10 AM
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update GlobeNewswire Inc. - 4/29/2020 6:00:10 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/8/2020 6:03:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:17:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:16:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:15:05 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:14:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:12:49 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:12:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/3/2020 5:01:27 PM
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority GlobeNewswire Inc. - 4/3/2020 6:59:09 AM
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer GlobeNewswire Inc. - 4/1/2020 9:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 7:52:11 AM
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors GlobeNewswire Inc. - 3/31/2020 4:00:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/18/2020 6:02:58 AM
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 GlobeNewswire Inc. - 3/16/2020 3:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/13/2020 5:02:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/13/2020 5:02:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/6/2020 5:07:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/6/2020 5:05:46 PM
Lorcan458   Monday, 11/06/17 04:54:11 PM
Re: None
Post # of 2686 
I read the 8K SEC filing and the new CFO, Eyal Rubin has a salary of $16,800 USD / month and was granted 25,000 shares that vest after 1 year. The $300,000 investment on the financial operations side at this early stage in the process of getting their first treatment to market brings up some questions to ponder:

1. Why so early in the process?
a. Are they so confident in eventual success, they want to get started on building their commercial side of the house right away?

b. Does his experience at TEVA indicate that the local choice, TEVA, is going to be the partner that brings a worldwide network of sales and distribution, worldwide regulatory legal experience, PR, etc?

c. Is Eyal going to raise money on the strength of the ALS results to be able to move other trials into Phase 2 before commercializing the ALS treatment?

2. Is Brainstorm planning to stay a development company and license for royalties or will they organically build up into an independent pharma company?

Comment: My gut feeling the royalty model because the worldwide overhead is too great. However, this treatment and technology isn't like traditional pharma where you need a salesforce promoting pills to each insurance carrier trying to get to be the recommended brand. I think the orphan status and patents will likely end up in a place where there is no real competition that can deliver the same or better results.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist